In children with severe eczema, targeted treatment boosts growth
New research from Trinity College Dublin has documented the significant impact of severe eczema on a child's height and shown, for the first time in a controlled study, that the right treatment can help improve growth.
A recent study conducted by researchers from Trinity College Dublin has revealed that targeted treatment with dupilumab, a biologic drug commonly used to treat severe eczema, can significantly boost growth in children with the condition. The research, published in the Journal of the American Academy of Dermatology, tracked the height and bone growth of 123 children aged 6 to 11 years old with severe eczema.
The findings suggest that early and effective treatment of severe eczema could have lifelong implications for a child's growth, potentially improving bone development and overall quality of life.
Written by urgent.news from Medical Xpress's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
